A drug that prevents elderly people losing their sight should be routinely available on the NHS, says the Royal College of Ophthalmologists.

Avastin has been found in clinical trials to be safe and effective for patients with wet Age-Related Macular Degeneration (AMD), a major cause of sight loss in older people. 

The Royal College says switching to the drug could save the NHS £100m.

Avastin is cheaper than the officially approved treatment, Lucentis. 

Both drugs are made by Roche - but Lucentis is marketed by Novartis in the UK.

For more details, go to: http://www.bbc.com/news/health-30138097